Efficacy of sibutramine in different types of eating behavior in obese patients ; Эффективность применения сибутрамина при различных типах нарушений пищевого поведения у пациентов с ожирением
Introduction. One of the key factors contributing to the development and progression of obesity is impairment eating behavior (EB). Therefore, drug therapy for obesity should not only reduce hunger, contributing to weight loss, but also reducing the severity of EB disorders.Aim. Assess the representation of different types of EB in obese patients, the effect of sibutramine therapy on dynamics EB by The Dutch Eating Behavior Questionnaire (DEBQ) and for hunger/satiety on a visual analog scale (VAS). Quality life of patients, adherence to treatment of obese patients and their weight dynamics in... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Verlag/Hrsg.: |
REMEDIUM GROUP Ltd.
|
Schlagwörter: | ВАШ (визуально-аналоговая шкала чувства голода/сытости) / sibutramine / eating behavior / The Dutch Eating Behavior Questionnaire (DEBQ) / HADS (Hospital Anxiety and Depression Scale) / VAS (visual analogue scale of hunger/fullness) / сибутрамин / пищевое поведение / голландский опросник пищевого поведения |
Sprache: | Russian |
Permalink: | https://search.fid-benelux.de/Record/base-26634597 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://www.med-sovet.pro/jour/article/view/6941 |
Introduction. One of the key factors contributing to the development and progression of obesity is impairment eating behavior (EB). Therefore, drug therapy for obesity should not only reduce hunger, contributing to weight loss, but also reducing the severity of EB disorders.Aim. Assess the representation of different types of EB in obese patients, the effect of sibutramine therapy on dynamics EB by The Dutch Eating Behavior Questionnaire (DEBQ) and for hunger/satiety on a visual analog scale (VAS). Quality life of patients, adherence to treatment of obese patients and their weight dynamics in different types of EB during therapy with sibutramine was also assessed.Materials and methods. The study included 36 obese patients (30 women and 6 men), mean age 38.7 ± 10.8 years, mean body weight 102.8 ± 16.4 kg, body mass index (BMI) 36.8 ± 4.6 kg/m2, receiving therapy with sibutramine at a dose of 10 mg per day once in the morning before meals in combination with hypocaloric nutrition.Results and discussion. The study showed the prevalence of the emotiogenic type of eating disorders in patients. However, it was pointed out that sibutramine therapy combined with hypocaloric nutrition proved its efficacy in any type of eating disorders. Positive dynamics anxiety/depression in subclinical conditions during treatment with sibutramine was also revealed.Conclusion. Sibutramine treatment may be recommended for the development of a new EB model in obese patients because it is effective in reducing weight in any type of EB disorder. ; Введение. Одним из ключевых факторов, способствующих развитию и прогрессированию ожирения, является нарушение пищевого поведения (ПП). Поэтому медикаментозная терапия ожирения должна не только снижать чувство голода, способствуя снижению веса, но и уменьшать выраженность нарушений ПП.Цель. Оценить представленность различных типов ПП у пациентов с ожирением, влияние терапии сибутрамином на динамику выраженности нарушений ПП с помощью Голландского опросника пищевого поведения (The Dutch Eating ...